Improved outcome in patients with acute myelogenous leukaemia post high-dose chemotherapy with the combination of BCNU, cytarabine, melphalan and autologous haematopoietic cell transplantation

被引：0
|
作者：
Sakellari, I. [1 ]
Mallouri, D. [1 ]
Apostolou, C. [1 ]
Antoniou, A. [1 ]
Batsis, I. [1 ]
Kaloyannidis, P. [1 ]
Kelaidi, C. [1 ]
Tsimperis, S. [1 ]
Smias, C. [1 ]
Papaioannou, G. [1 ]
Sotiropoulos, D. [1 ]
Dourvas, G. [1 ]
Saloum, R. [1 ]
Anagnostopoulos, A. [1 ]
Fassas, A. [1 ]
机构：
[1] G Papanicolaou Hosp, Thessaloniki, Greece
来源：
BONE MARROW TRANSPLANTATION | 2011年 / 46卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
下载
收藏
页码：S275 / S275
页数：1
相关论文
共 50 条
  • [21] Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for older patients with acute myelogenous leukemia
    Schiller, G
    Lee, M
    LEUKEMIA & LYMPHOMA, 1997, 25 (1-2) : 111 - 119
  • [22] POST REMISSION TREATMENT OF ADULT ACUTE MYELOGENOUS LEUKEMIA - HIGH-DOSE CYTARABINE FOR CONSOLIDATION CHEMOTHERAPY AND BONE-MARROW TRANSPLANTATION (BMT)
    CHAMPLIN, R
    HO, W
    WINSTON, D
    GALE, RP
    EXPERIMENTAL HEMATOLOGY, 1987, 15 (05) : 440 - 440
  • [23] High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma
    D Sivaraj
    W Bacon
    G D Long
    D A Rizzieri
    M E Horwitz
    K M Sullivan
    Y Kang
    Z Li
    N J Chao
    C Gasparetto
    Bone Marrow Transplantation, 2018, 53 : 34 - 38
  • [24] Cryotherapy in patients receiving high-dose melphalan followed by autologous stem cell transplantation
    Saevarsdottir, T.
    BONE MARROW TRANSPLANTATION, 2008, 41 : S403 - S403
  • [25] No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission
    Cahn, JY
    Labopin, M
    Sierra, J
    Blaise, D
    Reiffers, J
    Ferrant, A
    Bergmann, L
    Visani, G
    Cornelissen, J
    De Witte, T
    Bosi, A
    Frassoni, F
    Gorin, NC
    BRITISH JOURNAL OF HAEMATOLOGY, 2000, 110 (02) : 308 - 314
  • [26] High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma
    Sivaraj, D.
    Bacon, W.
    Long, G. D.
    Rizzieri, D. A.
    Horwitz, M. E.
    Sullivan, K. M.
    Kang, Y.
    Li, Z.
    Chao, N. J.
    Gasparetto, C.
    BONE MARROW TRANSPLANTATION, 2018, 53 (01) : 34 - 38
  • [27] Behenoyl cytarabine-based chemotherapy followed by haematopoietic stem cell transplantation for paediatric non-promyelocytic acute myelogenous leukaemia
    Yoo, K. H.
    Sung, K. W.
    Cho, E. J.
    Lee, S. Y.
    Kim, J. Y.
    Jung, H. L.
    Koo, H. H.
    BONE MARROW TRANSPLANTATION, 2008, 41 : S115 - S115
  • [28] Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation
    Donato, ML
    Feasel, AM
    Weber, DM
    Prieto, VG
    Giralt, SA
    Champlin, RE
    Duvic, M
    BLOOD, 2006, 107 (02) : 463 - 466
  • [29] POSTREMISSION CHEMOTHERAPY FOR ADULTS WITH ACUTE MYELOGENOUS LEUKEMIA - IMPROVED SURVIVAL WITH HIGH-DOSE CYTARABINE AND DAUNORUBICIN CONSOLIDATION TREATMENT
    CHAMPLIN, R
    GAJEWSKI, J
    NIMER, S
    VOLLSET, S
    LANDAW, E
    WINSTON, D
    SCHILLER, G
    HO, W
    JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (07) : 1199 - 1206
  • [30] High-dose chemotherapy with tandem autologous haematopoietic cell transplantation followed by the combination treatment with bortezomib, thalidomide and dexamethasone for plasma cell leukaemia associated with POEMS syndrome - a case report
    Kata, D
    Krzemien, S
    Nowak, K
    Holowiecki, J
    BONE MARROW TRANSPLANTATION, 2006, 37 : S143 - S143
12345